MedTrace Logo

MAtrix Therapy for Hard-to-heal ChrOnic Wounds

NCT05170984 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 191

Last updated 2026-04-13

No results posted yet for this study

Summary

CACIPLIQ20® is currently a class III CE marked medical device available in various European and non-European countries, and currently primarily used in managing hard-to-heal wounds.

This study is a prospective and standardized recording of patients' data followed in real-life conditions to appreciate the benefits of a therapeutic strategy including CACIPLIQ20® use. It also aims at collecting data to follow-up the device's efficacy and safety and estimate its cost-effectiveness.

Conditions

  • Chronic Ulcer of Leg or Foot
  • Diabetic Foot Ulcer
  • Arterial Ulcer
  • Venous Ulcer of Leg

Interventions

DEVICE

CACIPLIQ20®

Application of CACIPLIQ20® by spray, directly on the wound surface, after wound cleaning and debridement, twice a week, until wound closure (or up to 20 weeks maximum).

Sponsors & Collaborators

  • Organ, Tissue, Regeneration, Repair and Replacement

    lead INDUSTRY

Principal Investigators

  • Luc TEOT, MD, PhD · Réseau Cicat-Occitanie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-10
Primary Completion
2024-07-01
Completion
2024-12-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05170984 on ClinicalTrials.gov